托吡酯诱发的持续性视觉模糊：病例系列报道及文献综述

Topiramate-induced palinopsia: a case series and review of the literature.

作者信息

Yun Samuel H, Lavin Patrick J, Schatz Martha P, Lesser Robert L

机构信息

Department of Ophthalmology and Visual Sciences (SHY, RLL), Yale School of Medicine, New Haven, Connecticut; Departments of Neurology, and Ophthalmology and Visual Sciences (PL), Vanderbilt University School of Medicine, Nashville, Tennessee; and Department of Ophthalmology (MS), University of Texas Health Science Center, San Antonio, Texas.

出版信息

J Neuroophthalmol. 2015 Jun;35(2):148-51. doi: 10.1097/WNO.0000000000000216.

DOI:10.1097/WNO.0000000000000216

PMID:25634739

Abstract

BACKGROUND

To report palinopsia as a possible side effect of topiramate.

METHODS

Case series and review of the literature.

RESULTS

Nine patients in our series, and 4 previously reported patients, who developed palinopsia while on topiramate, are reviewed. All patients were women, and comorbidities included migraine, idiopathic intracranial hypertension, and bulimia nervosa. Palinopsia resolved in 8 patients after stopping or decreasing the dose of topiramate. The lowest dose of topiramate causing palinopsia was 25 mg twice a day. More than half of our patients reported exacerbation of visual disturbance in early morning or late evening.

CONCLUSIONS

Topiramate-induced palinopsia may be underdiagnosed because physicians do not inquire about such visual symptoms.

摘要

背景

报告托吡酯可能产生的一个副作用——持续性视觉障碍。

方法

病例系列研究及文献综述。

结果

对我们研究系列中的9例患者以及之前报道的4例在服用托吡酯时出现持续性视觉障碍的患者进行了回顾。所有患者均为女性，合并症包括偏头痛、特发性颅内高压和神经性贪食症。8例患者在停用或减少托吡酯剂量后持续性视觉障碍症状消失。导致持续性视觉障碍的托吡酯最低剂量为每日两次，每次25毫克。我们半数以上的患者报告在清晨或傍晚视觉障碍加重。